BUYINS.NET Issues Zynex (ZYXI) SqueezeTrigger Report
M2 - Fri May 15, 7:12AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Zynex, Inc. (OTC: ZYXI) after releasing the latest short sale data through May 14, 2015. The total aggregate number of shares shorted since August 2009 is approximately 7.26 million shares. Approximately 36.52% of daily trading volume is short selling. The SqueezeTrigger price for all ZYXI shares shorted is $0.66. A short squeeze is expected to begin when shares of ZYXI close above the $0.66 SqueezeTrigger price.
Zynex Announces First Quarter 2015 Results
Marketwired - Tue May 12, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy, announced today first quarter 2015 financial results.
Zynex Schedules First Quarter 2015 Earnings Release and Webcast
Marketwired - Wed May 06, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host the Company's first quarter investor webcast on Tuesday, May 12, 2015 at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time).
Zynex provides financial update
M2 - Thu Apr 16, 7:04AM CDT
Electrotherapy medical company Zynex (Other OTC:ZYXI) on Wednesday updated its turnaround of operations and financial estimate for the first and second quarters of 2015 as well as plans to release its first quarter earnings on or before 15 May 2015.
Zynex, Inc. Provides Financial Update
GlobeNewswire - Thu Apr 16, 6:39AM CDT
via PRWEB - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and stroke rehabilitation, and transdermal pain creams, provides update on its turnaround of operations and financial estimate for the first and second quarters of 2015.
Zynex's (ZYXI) CEO Thomas Sandgaard on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 02, 12:29PM CDT
Zynex Announces 2014 Year End Results
Marketwired - Thu Apr 02, 7:01AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today 2014 year-end financial results.
Zynex Receives 43rd Pharmacy License Approval
PRWeb - Mon Mar 30, 8:09AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it has received license approval from the State of Oregon for its compound pharmacy business Pharmazy. This brings to 43 the total states, including the District of Columbia, in which the Company is licensed to provide compound pharmacy services.
Zynex Schedules 2014 Year End Earnings Conference Call and Webcast
Marketwired - Thu Mar 26, 7:00AM CDT
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host an investor webcast on Thursday, April 2, 2015 at 11:00 a.m. ET (9:00 a.m. MT) to discuss the Company's 2014 year-end results.
Zynex wins its 42nd pharmacy licence in Kentucky
M2 - Thu Mar 19, 6:51AM CDT
Medical technology company Zynex (OtherOTC:ZYXI) reported on Wednesday the receipt of licence approval for its compound pharmacy business Pharmazy in the State of Kentucky.
Zynex, Inc. Hires Two Key Managers for Compliance and Quality
GlobeNewswire - Fri Feb 13, 4:06AM CST
via PRWEB - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today the recent hire of Colin Glennan, CHC as Director of Compliance and Todd Romero as Director of Quality.
Zynex Provides Operations Update
Marketwired - Mon Jan 05, 12:43PM CST
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today the following operational updates for shareholders:
Zynex Achieves Compound Pharmacy License Approval in 40th State
Marketwired - Thu Nov 20, 7:57AM CST
Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pain creams, announced today that it attained compound pharmacy licensing approval in the state of Iowa, marking its fortieth state approval.
Zynex beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:04AM CST